Coronavirus drugs research firm WuXi Biologics’ largest shareholder sells stake for US$893 million windfall | South China Morning Post

Coronavirus drugs research firm WuXi Biologics’ largest shareholder sells stake for US$893 million windfall | South China Morning Post

More reads

• WuXi Biologics’ largest shareholder sells stake for $893 million windfall (South China Morning Post)
• China biotech InxMed bags $19M Series A+ to develop PhI FAK inhibitor (Endpoints News)
• Chinese biopharma firm Adlai Nortye raises $100M In Series C round (China Money Network)
• China's CNBG, Sinovac find more countries to test coronavirus vaccines (Reuters)